DrugCentral 2023 extends human clinical data and integrates veterinary drugs.
Nucleic Acids Res
; 51(D1): D1276-D1287, 2023 01 06.
Article
in English
| MEDLINE | ID: covidwho-2189411
ABSTRACT
DrugCentral monitors new drug approvals and standardizes drug information. The current update contains 285 drugs (131 for human use). New additions include (i) the integration of veterinary drugs (154 for animal use only), (ii) the addition of 66 documented off-label uses and iii) the identification of adverse drug events from pharmacovigilance data for pediatric and geriatric patients. Additional enhancements include chemical substructure searching using SMILES and 'Target Cards' based on UniProt accession codes. Statistics of interests include the following (i) 60% of the covered drugs are on-market drugs with expired patent and exclusivity coverage, 17% are off-market, and 23% are on-market drugs with active patents and exclusivity coverage; (ii) 59% of the drugs are oral, 33% are parenteral and 18% topical, at the level of the active ingredients; (iii) only 3% of all drugs are for animal use only; however, 61% of the veterinary drugs are also approved for human use; (iv) dogs, cats and horses are by far the most represented target species for veterinary drugs; (v) the physicochemical property profile of animal drugs is very similar to that of human drugs. Use cases include azaperone, the only sedative approved for swine, and ruxolitinib, a Janus kinase inhibitor.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Drug Approval
/
Veterinary Drugs
/
Drug-Related Side Effects and Adverse Reactions
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Nucleic Acids Res
Year:
2023
Document Type:
Article
Affiliation country:
Nar
Similar
MEDLINE
...
LILACS
LIS